Richard E. Higgs

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates”.

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Science Translational Medicine(2021)10.1126/scitranslmed.abf1906

N/A

0.933DataRank · unranked

503 citations

Patricia Brown‐Augsburger, Kizzmekia S. Corbett, Kathryn Westendorf, Julian Davies, Thomas P. Cujec +52 more

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Cell Reports(2022)10.1016/j.celrep.2022.110812

N/A

0.921DataRank · unranked

464 citations

Stefanie Žentelis, Lingshu Wang, Denisa Foster, Peter Vaillancourt, Matthew Wiggin +64 more

The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination

medRxiv(2021)10.1101/2021.12.15.21267605

N/A

0.292DataRank · unranked

6 citations

Jay Tuttle, Lin Zhang, Josh Poorbaugh, Nicole L. Kallewaard, Peter Vaillancourt +11 more

Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials

Lara D. Veeken(2021)10.1093/rheumatology/keab144

N/A

0DataRank · unranked

3 citations

Steven Watts, Richard E. Higgs, Matthew D. Linnik, Michelle Petri

The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

UNC Libraries(2022)10.17615/77w4-hz26

N/A

0DataRank · unranked

1 citations

Nicole L. Kallewaard, Stephanie Beasley, Montanea Daniels, Joshua J. Freitas, Robert J. Benschop +11 more

The therapeutic monoclonal antibody bamlanivimab does not enhance SARS‑CoV-2 infection by FcR-mediated mechanisms

Research Square(2022)10.21203/rs.3.rs-2285240/v1

N/A

0DataRank · unranked

1 citations

Christopher M. Wiethoff, Patricia Brown‐Augsburger, Shawn Berens, Jamie L. Blackbourne, Ling Liu +25 more

The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms

Pathogens(2023)10.3390/pathogens12121408

N/A

0DataRank · unranked

5 citations

Christopher M. Wiethoff, Patricia Brown‐Augsburger, Shawn Berens, Jamie L. Blackbourne, Ling Liu +25 more